Opyl Ltd (ASX:OPL) has developed a software that uses artificial intelligence (AI) to make a probability of success prediction on the likelihood of a vaccine, drug, diagnostic or medical device succeeding in clinical trials.
Refining clinical trials
Previous studies demonstrated that on average only 13.8% of all drugs in phase 1 clinical trials eventually win approval from regulators and enter the market.
Typically, vaccines have a higher success rate (33.4%) than most other drugs, while cancer drugs have a far lower rate of success (3%).
The application of the Opyl software platform is to work with drug and device development companies to refine their clinical trial approaches to improve the outcomes of their clinical studies, which reduces costs and accelerates the timeline to get new treatments to patients.
Success prediction tool
Opyl chief executive officer Michelle Gallaher said: “We can see significant value in using the tool to inform clinical and treatment strategies, early procurement decision making and investments.
“The early outcome of this software trial, investigating the 475 registered COVID19 clinical trials related to vaccines or treatments, has delivered results that give us an indication of the power of the predictive platform in identifying the COVID19 trials, or any drug or device trial, with the greatest chance of success.
“Our approach is to use AI to not just predict the outcome, but to demonstrate that changing specific clinical trials variables can improve the probability of success.
“Our goal is to improve the efficiency, improve the application of research funding and ultimately the return on investment for scientists, clinicians, health technology developers and investors.”
With hundreds of COVID19 clinical trials currently being undertaken around the globe, the company has available data for its AI platform.
The AI Platform uses current and historical global data and considers everything from the numbers of participants in each trial; the dropout rate from those trials; how long each trial will take; the end point for each trial relative to related studies, through to the mode of action such as type of protein or vector being employed in a program.
The next stage of the platform’s development will involve increasing the data pool from additional clinical data sources and expanding the variables in order to further train the algorithm and refine the specificity and reliability.
Opyl is reaching out to those groups, such as governments and collaboration organisations that may have an interest in the findings from the COVID-19 work, as well as ongoing discussions with companies and partners on other applications of the technology.
Opyl shares have been granted a trading halt pending a response by Opyl to ASX queries.
The trading halt will remain in place until Opyl makes an announcement to the market or Monday, September 7, 2020, whichever is earlier.